🧠 Spasticity and Bladder Dysfunction Management Simulator

Baseline Spasticity and Neurogenic Bladder in MS

Demyelination disrupts descending and bladder-control signaling.

• 3.4: Ashworth score (severe baseline tone)
• 8/day: Urgency episodes (untreated detrusor activity)
• ~80%: MS prevalence w/ spasticity (placeholder figure)
• ~75%: MS prevalence w/ bladder sx (placeholder figure)

Corticospinal demyelination and hypertonia

Lesions disrupt inhibitory signaling, raising resting muscle tone.

Neurogenic detrusor overactivity

Disrupted bladder-control pathways trigger urgency and frequency.

Baclofen and Tizanidine — Reducing Muscle Tone

GABA-B and alpha-2 agonism dampen excitatory spinal reflexes.

• GABA-B: Baclofen mechanism (presynaptic inhibition)
• Alpha-2: Tizanidine mechanism (agonist, spinal interneurons)
• 10–80 mg: Typical dose range (baclofen, divided doses)
• Sedation: Main side effect (dose-limiting factor)

GABA-B agonism (baclofen)

Inhibits calcium influx at spinal afferents, reducing reflex excitability.

Alpha-2 agonism (tizanidine)

Suppresses excitatory interneuron output at the spinal cord level.

Anticholinergics — Calming Detrusor Overactivity

Muscarinic receptor blockade reduces involuntary bladder contractions.

• Anticholinergic: Drug class (e.g. oxybutynin)
• M3 muscarinic: Target receptor (detrusor smooth muscle)
• 5–20 mg: Typical dose range (oxybutynin, daily)
• Dry mouth: Main side effects (constipation, blurred vision)

Muscarinic receptor blockade

Blocks acetylcholine binding, relaxing detrusor smooth muscle.

Urgency and frequency reduction

Fewer involuntary contractions lower daily urgency episode counts.

Balancing Dual Symptom Control Against Side-Effect Burden

Sedation and anticholinergic effects compound as both doses rise.

• Additive: Combined burden (sedation + dry mouth risk)
• Stepwise: Titration approach (lowest effective dose)
• Ongoing: Monitoring (tone, voiding diary, alertness)
• Balance: Goal (function over full suppression)

Cumulative CNS and anticholinergic load

Both drug classes add sedative and cognitive burden together.

Individualized dose finding

Slow titration finds the smallest doses controlling both symptoms.

Dual-Symptom Control and Quality of Life

Optimized titration improves mobility, continence, and daily function.

• ~1.0: Ashworth improvement (from baseline 3.4)
• ~2/day: Urgency reduction (from baseline 8/day)
• Low: Side-effect burden (balanced dosing achieved)
• Improved: Quality of life (mobility + continence gains)

Sustained dual-symptom management

Ongoing monitoring maintains balance as MS symptoms fluctuate.

Functional and continence gains

Reduced tone and urgency together restore daily independence.